BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22002241)

  • 21. CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells.
    Koschella M; Voehringer D; Pircher H
    J Immunol; 2004 Apr; 172(8):4804-11. PubMed ID: 15067057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
    Nowak AK; Robinson BW; Lake RA
    Cancer Res; 2003 Aug; 63(15):4490-6. PubMed ID: 12907622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
    Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
    J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease.
    Gu T; Kilinc MO; Egilmez NK
    Cancer Immunol Immunother; 2008 Jul; 57(7):997-1005. PubMed ID: 18049819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.
    Lode HN; Xiang R; Pertl U; Förster E; Schoenberger SP; Gillies SD; Reisfeld RA
    J Clin Invest; 2000 Jun; 105(11):1623-30. PubMed ID: 10841521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
    Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
    J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.
    Puliaev R; Puliaeva I; Welniak LA; Ryan AE; Haas M; Murphy WJ; Via CS
    J Immunol; 2008 Jul; 181(1):47-61. PubMed ID: 18566369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4+ and CD8+ T cell priming for contact hypersensitivity occurs independently of CD40-CD154 interactions.
    Gorbachev AV; Heeger PS; Fairchild RL
    J Immunol; 2001 Feb; 166(4):2323-32. PubMed ID: 11160289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
    Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
    J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential CD40/CD40L expression results in counteracting antitumor immune responses.
    Murugaiyan G; Agrawal R; Mishra GC; Mitra D; Saha B
    J Immunol; 2007 Feb; 178(4):2047-55. PubMed ID: 17277108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection.
    Shedlock DJ; Whitmire JK; Tan J; MacDonald AS; Ahmed R; Shen H
    J Immunol; 2003 Feb; 170(4):2053-63. PubMed ID: 12574376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD40-activated B cells induce anti-tumor immunity in vivo.
    Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells.
    Lefrançois L; Altman JD; Williams K; Olson S
    J Immunol; 2000 Jan; 164(2):725-32. PubMed ID: 10623816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognate CD4 help is essential for the reactivation and expansion of CD8 memory T cells directed against the hematopoietic cell-specific dominant minor histocompatibility antigen, H60.
    Ryu SJ; Jung KM; Yoo HS; Kim TW; Kim S; Chang J; Choi EY
    Blood; 2009 Apr; 113(18):4273-80. PubMed ID: 19139082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
    Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
    Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
    Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
    Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
    Carpenter EL; Mick R; Rüter J; Vonderheide RH
    J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.